期刊文献+

乳腺癌内分泌治疗的药学监护 被引量:1

Pharmaceutical care of breast cancer patients with endocrinotherapy
下载PDF
导出
摘要 目的:探讨临床药师在乳腺癌内分泌治疗中进行药学服务的切入点。方法:通过分析临床药师参与乳腺癌病人内分泌治疗的3个典型病例,结合内分泌治疗特点,对进行内分泌治疗病人的药学监护提出建议。结果:临床药师在内分泌治疗过程中,从正确判断绝经状态、提高内分泌治疗依从性和持续性、关注药物相互作用三方面入手,及时发现并解决药物治疗相关问题,保证治疗有效和持续进行。结论:正确判断绝经状态、提高治疗依从性和持续性、关注药物相互作用,是临床药师在乳腺癌内分泌治疗中进行药学服务的主要切入点。 Objective: To explore the approach of pharmaceutical care by clinical pharmacists in endocrinotherapy of pa tients with breast cancer. Methods: Recommendations were made in the pharmaceutical care of patients with endocrinotherapy, through analyses of 3 typical breast cancer cases with clinical pharmacists involved in endocrinotherapy, and the features of endocrinotherapy as well. Results: In the process of endocrinotherapy, related problems concerning medication were identified and solved in a timely manner, through correct judgment on menopausal status, enhanced endocrine treatment compliance and per sistence, as well as drug interactions. As a consequence, persistent and effective treatment results were achieved. Conclusion: Correct judgment on menopausal status, enhanced endocrine treatment compliance and persistence, and attention to drug inter actions are main approaches to pharmaceutical care by clinical pharmacists in endocrinotherapy of breast cancer.
作者 胡兰 姚莉
出处 《药学服务与研究》 CAS CSCD 2014年第6期425-427,共3页 Pharmaceutical Care and Research
关键词 乳腺癌 药物疗法 内分泌 药学服务 breast cancer drug therapy,endocrine pharmaceutical care
  • 相关文献

参考文献9

  • 1郑莹,吴春晓,张敏璐.乳腺癌在中国的流行状况和疾病特征[J].中国癌症杂志,2013,23(8):561-569. 被引量:852
  • 2Smith I E, Dowsett M, Yap Y S, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy induced amenorrhoea caution and suggested guidelines [J]. J Clin 0ncol,2006,24(16)2444-2447.
  • 3中国绝经前女性乳腺癌患者辅助治疗后绝经判断标准及芳香化酶抑制剂临床应用共识[J].中国癌症杂志,2012,22(3):238-240. 被引量:7
  • 4Davies C, Pan H, Godwin J, etal. Long term effects of con tinuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381 (9869):805 816.
  • 5Hershman DL, KushiL H, ShaoT, etal. Early discontinua- tion and nonadherence to adiuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients[J]. J Clin Oncol,2010,28(27) :4120-4128.
  • 6Mortimer J E, Flatt SW, Parker B A, etal. Tamoxifen, hot flashes and recurrence in breast cancer[J]. Breast Cancer Res Treat, 2008,108(3) : :421-426.
  • 7Kelly C M, JuurlinkDN, Gomes T, etal. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study[J]. BMJ, 2010,340 : c693-c700.
  • 8Zafra-Ceres M, de Haro T, Farez Vidal E, etal. Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabo- lites in Spanish women with breast cancer[J]. Int J Med Sci, 2013,10(7) :932-937.
  • 9Ruddy K .1, Desantis S D, Gelman R S, et aK Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice[J]. Breast Cancer Res Treat, 2013,141 (3) : 421 427.

二级参考文献43

  • 1王启俊,祝伟星,邢秀梅.北京城区女性乳腺癌发病死亡和生存情况20年监测分析[J].中华肿瘤杂志,2006,28(3):208-210. 被引量:81
  • 2陈建国,朱健,张永辉.启东市1972~2000年主要恶性肿瘤生存率分析[J].中国肿瘤,2006,15(9):575-578. 被引量:34
  • 3李惠平,马力文,张淑兰,贾廷珍,邓惠静,张照辉,梁莉,王墨培,肖宇,曹保山,陈森,汪有蕃.绝经前乳腺癌化疗致闭经的观察及临床意义[J].中华肿瘤杂志,2006,28(11):848-851. 被引量:23
  • 4OKTAY K, SONMERZER M. Chemotherapy and amenorrhea: risks and treatment options [ J ] . Curr Opin Obstet Gynecol, 2008, 20(4): 408-415.
  • 5KIL W J, AHN S D, SHIN S S, et al. Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients [ J ] . Breast Cancer Res Treat, 2006, 96(3): 245- 250.
  • 6PETREK J A, NAUGHTON M J, CASE L D, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study [ J ] . J Clin Oncol, 2006, 24(7): 1045-1051.
  • 7FORNIER M N, MODI S, PANAGEAS K S, et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane [ J ] . Cancer, 2005, 104(8): 1575- 1579.
  • 8THAM Y L, SEXTON K, WEISS H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and eyelophosphamide followed by a taxane [ J ]. Am J Clin Oncol, 2007, 30(2): 126-132.
  • 9SWAIN S M, LAND S R, SUNDRY J, et al. Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C)---~docetaxel (1') arm of NSABP B-30: preliminary results [ J ] . Proc Am Soc Clin Oncol, 2005, 23(Suppl 16): 537.
  • 10COOMBES R C, KILBURN L S, SNOWDON C F, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trim [ J ] . Lancet, 2007, 369(9561): 559-570.

共引文献857

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部